London, 28 November 2016 – Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, announces that data on two of its novel cell therapies will be presented at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego, CA, December 3-6, 2016.

Details of the oral presentations are as follows:

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo